Top-Rated Stocks NASDAQ:QURE uniQure Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. $19.11 -0.43 (-2.20%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$18.18▼$19.9550-Day Range$13.15▼$19.5452-Week Range$12.52▼$38.80Volume1.62 million shsAverage Volume581,604 shsMarket Capitalization$891.44 millionP/E Ratio2.77Dividend YieldN/APrice Target$49.43 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Email Address QURE Stock Forecast (MarketRank)Overall MarketRank™2.53 out of 5 starsMedical Sector108th out of 1,418 stocksPharmaceutical Preparations Industry37th out of 679 stocksAnalyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatinguniQure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.43, uniQure has a forecasted upside of 158.7% from its current price of $19.11.Amount of Analyst CoverageuniQure has only been the subject of 1 research reports in the past 90 days. Previous Next 4.8 Community Rank Outperform VotesuniQure has received 619 “outperform” votes. (Add your “outperform” vote.)Underperform VotesuniQure has received 236 “underperform” votes. (Add your “underperform” vote.)Community SentimentuniQure has received 72.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about uniQure and other stocks. Vote “Outperform” if you believe QURE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,334.00 in company stock.Percentage Held by InsidersOnly 2.66% of the stock of uniQure is held by insiders.Percentage Held by Institutions81.35% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.54) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is 2.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 13.72.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is 2.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 12.33.Price to Book Value per Share RatiouniQure has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About uniQure (NASDAQ:QURE)uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Read More QURE Stock News HeadlinesJune 23, 2022 | americanbankingnews.comChristian Klemt Sells 1,687 Shares of uniQure (NASDAQ:QURE) StockJune 22, 2022 | americanbankingnews.comuniQure (NASDAQ:QURE) COO Pierre Caloz Sells 7,575 SharesJune 9, 2022 | americanbankingnews.comuniQure (NASDAQ:QURE) Upgraded to "Hold" by StockNews.comJune 9, 2022 | americanbankingnews.comCantor Fitzgerald Weighs in on uniQure's FY2023 Earnings (NASDAQ:QURE)February 7, 2022 | globenewswire.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireFebruary 7, 2022 | finance.yahoo.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseFebruary 5, 2022 | washingtonpost.comWith CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington PostFebruary 4, 2022 | finance.yahoo.comGlobal Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo FinanceFebruary 4, 2022 | reuters.comAmazon has a unique inflation problem - ReutersFebruary 3, 2022 | washingtonpost.comTurkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington PostFebruary 2, 2022 | forbes.comLooking To Fill Unique Sports Merchandise Void, ‘Official League’ Launches Lifestyle Brand - ForbesFebruary 2, 2022 | bbc.comDeliberate infections give unique Covid insight - BBC NewsJanuary 31, 2022 | pymnts.comWhat Makes the UE’s Digital Markets Act Unique - pymnts.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QURE CUSIPN/A CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees463Year FoundedN/ACompany Calendar Last Earnings5/02/2022Today6/24/2022Next Earnings (Estimated)7/25/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$49.43 High Stock Price Forecast$66.00 Low Stock Price Forecast$27.46 Forecasted Upside/Downside+158.7%Consensus RatingBuy Rating Score (0-4)3 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$6.89 Trailing P/E Ratio2.77 Forward P/E RatioN/A P/E GrowthN/ANet Income$329.59 million Net Margins61.76% Pretax Margin62.22% Return on Equity54.85% Return on Assets41.53% Debt Debt-to-Equity Ratio0.19 Current Ratio12.94 Quick Ratio12.94 Sales & Book Value Annual Sales$524 million Price / Sales1.70 Cash Flow$9.06 per share Price / Cash Flow2.11 Book Value$12.89 per share Price / Book1.48Miscellaneous Outstanding Shares46,648,000Free Float45,407,000Market Cap$891.44 million OptionableOptionable Beta1.13 uniQure Frequently Asked Questions Should I buy or sell uniQure stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" uniQure stock. View analyst ratings for uniQure or view top-rated stocks. What is uniQure's stock price forecast for 2022? 8 brokers have issued twelve-month target prices for uniQure's stock. Their QURE stock forecasts range from $27.46 to $66.00. On average, they predict uniQure's stock price to reach $49.43 in the next twelve months. This suggests a possible upside of 158.7% from the stock's current price. View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts. How has uniQure's stock performed in 2022? uniQure's stock was trading at $20.74 at the start of the year. Since then, QURE shares have decreased by 7.9% and is now trading at $19.11. View the best growth stocks for 2022 here. When is uniQure's next earnings date? uniQure is scheduled to release its next quarterly earnings announcement on Monday, July 25th 2022. View our earnings forecast for uniQure. How were uniQure's earnings last quarter? uniQure (NASDAQ:QURE) posted its quarterly earnings data on Monday, May, 2nd. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.33. The biotechnology company earned $1.79 million during the quarter, compared to analysts' expectations of $51.23 million. uniQure had a net margin of 61.76% and a trailing twelve-month return on equity of 54.85%. View uniQure's earnings history. Who are uniQure's key executives? uniQure's management team includes the following people: Mr. Matthew Craig Kapusta, CEO & Exec. Director (Age 50, Pay $969.95k) (LinkedIn Profile)Mr. Christian Klemt, CFO, Principal Financial Officer & GM of Amsterdam Site (Age 49, Pay $505.02k) (LinkedIn Profile)Mr. Pierre Caloz, Chief Operating OfficerDr. Alexander E. Kuta Ph.D., Exec. VP of Quality & Regulatory (Age 62, Pay $649.26k)Dr. Ricardo Dolmetsch Ph.D., Pres of R&D (Age 53, Pay $795.35k) (LinkedIn Profile)Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-GermanyMr. David Cerveny, Chief Legal Officer, Gen. Counsel & Sec. (Age 55)Dr. Tamara Tugal Ph.D., MBA, Bus. Devel. DirectorMs. Erin Boyer, Chief People & Culture OfficeMs. Maria E. Cantor, Chief Corp. Affairs Officer (Age 54) What is Matthew Kapusta's approval rating as uniQure's CEO? 8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees. Who are some of uniQure's key competitors? Some companies that are related to uniQure include Karuna Therapeutics (KRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), CureVac (CVAC), Indivior (INVVY), Pacira BioSciences (PCRX), Insmed (INSM), Corcept Therapeutics (CORT), Arvinas (ARVN) and ACADIA Pharmaceuticals (ACAD). View all of QURE's competitors. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE). What is uniQure's stock symbol? uniQure trades on the NASDAQ under the ticker symbol "QURE." Who are uniQure's major shareholders? uniQure's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.36%), State Street Corp (6.03%), Vanguard Group Inc. (2.59%), JPMorgan Chase & Co. (1.90%), Bank of New York Mellon Corp (1.45%) and Federated Hermes Inc. (1.28%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Leonard E Post, Matthew C Kapusta, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Pierre Caloz, Ricardo Dolmetsch and Robert Gut. View institutional ownership trends for uniQure. Which institutional investors are selling uniQure stock? QURE stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Federated Hermes Inc., Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, Henry James International Management Inc., Citigroup Inc., Jane Street Group LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold uniQure company stock in the last two years include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Pierre Caloz, Ricardo Dolmetsch, and Robert Gut. View insider buying and selling activity for uniQure or view top insider-selling stocks. Which institutional investors are buying uniQure stock? QURE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Assenagon Asset Management S.A., JPMorgan Chase & Co., Acadian Asset Management LLC, BlackRock Inc., Integral Health Asset Management LLC, UBS Group AG, and Robeco Institutional Asset Management B.V.. View insider buying and selling activity for uniQure or or view top insider-buying stocks. How do I buy shares of uniQure? Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is uniQure's stock price today? One share of QURE stock can currently be purchased for approximately $19.11. How much money does uniQure make? uniQure (NASDAQ:QURE) has a market capitalization of $891.44 million and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or $6.89 on an earnings per share basis. How many employees does uniQure have? uniQure employs 463 workers across the globe. How can I contact uniQure? uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for uniQure is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272. This page (NASDAQ:QURE) was last updated on 6/25/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here